Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the P/S ratio high or low?
The P/S ratio of 1.81 is 79% below its estimated 5-year average of 8.67, near the low end of its estimated 5-year range (1.81–61.39).
As of 2026-10-06T15:40:52.938Z. 46.69% below its estimated 12-month average of 3.40.
Calculation as of: 2026-10-06T15:40:52.938Z.
Quote observation: 2026-10-06T15:40:30.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d9de0dbfadb283a207fe687abae4d6c7414f83280ed3d33a9edf26fe3e5e7dd3
Current P/S: FMP quote market capitalization / TTM revenue. Historical estimates use price and reported weighted-average shares; daily points use adjusted close × quarterly weighted-average shares / TTM revenue. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
1.81
PS RATIO AVG TTM
3.40
PS RATIO AVG 3Y
5.27
PS RATIO AVG 5Y
8.67
PS RATIO AVG 10Y
11.98
PS RATIO AVG 15Y
N/A
PS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-46.69%
CURRENT VS 3Y AVG
-65.67%
CURRENT VS 5Y AVG
-79.13%
CURRENT VS 10Y AVG
-84.90%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
4.11
median of 467 covered companies
CURRENT VS SECTOR MEDIAN
-55.96%
vs the sector median at left
Market Cap
$816.88M
PS Ratio
5.13
TTM Avg
3.19
3Y Avg
4.02
5Y Avg
10.18
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ardelyx, Inc. (ARDX) | $817.67M | 1.81 | 3.40 | 5.27 | 8.67 |
| Pacific Biosciences of California, Inc. (PACB)vs › | $816.88M | 5.13 | 3.19 | 4.02 | 10.18 |
| Apnimed, Inc. (APMD)vs › | $804.43M | N/A | N/A | N/A | N/A |
| InMode Ltd. (INMD)vs › | $805.59M | 2.15 | 2.45 | 3.11 | 6.00 |
| Jade Biosciences, Inc. (JBIO)vs › | $834.69M | N/A | N/A | N/A | N/A |
| Gyre Therapeutics, Inc. (GYRE)vs › | $799.93M | 6.70 | 6.23 | 9.08 | 36.05 |
| AdaptHealth Corp. (AHCO)vs › | $795.49M | 0.26 | 0.48 | 0.44 | 0.69 |
| QuidelOrtho Corporation (QDEL)vs › | $841.20M | 0.31 | 0.49 | 0.82 | 1.32 |
| Beta Bionics, Inc. (BBNX)vs › | $843.41M | 7.09 | 8.02 | 9.17 | 9.17 |
| Geron Corporation (GERN)vs › | $789.07M | 3.86 | 4.98 | 1623.75 | 1489.80 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $110,329,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-30 |
| Q4 FY2025Period ended 2025-12-31 | $125,215,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-19 |
| Q1 FY2026Period ended 2026-03-31 | $94,473,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-30 |
| Q2 FY2026Period ended 2026-06-30 | $120,877,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $450,894,000 |
Current P/S: $817,665,990 market capitalization ÷ $450,894,000 TTM revenue = 1.81x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T15:40:30.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
At 1.81, P/S is below its estimated 12-year median — higher than 11% of readings in its estimated 12-year history.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
estimated 12-year low
0.58
median
7.11
estimated 12-year high
357.69
P/S Ratio
1.81
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PS RATIO |
|---|---|
| 2026-10-05 | 1.87 |
| 2026-10-02 | 1.84 |
| 2026-10-01 | 1.86 |
| 2026-09-30 | 1.88 |
| 2026-09-29 | 1.87 |
| 2026-09-28 | 1.88 |
| 2026-09-25 | 1.88 |
| 2026-09-24 | 1.90 |
| 2026-09-23 | 1.91 |
| 2026-09-22 | 1.99 |
| 2026-09-21 | 1.93 |
| 2026-09-18 | 1.88 |
| 2026-09-17 | 1.86 |
| 2026-09-16 | 1.87 |
| 2026-09-15 | 1.87 |
| 2026-09-14 | 1.94 |
| 2026-09-11 | 1.97 |
| 2026-09-10 | 1.99 |
| 2026-09-09 | 2.09 |
| 2026-09-08 | 2.07 |
| 2026-09-04 | 2.08 |
| 2026-09-03 | 2.04 |
| 2026-09-02 | 2.09 |
| 2026-09-01 | 2.07 |
| 2026-08-31 | 2.08 |
| 2026-08-28 | 2.10 |
| 2026-08-27 | 2.10 |
| 2026-08-26 | 2.11 |
| 2026-08-25 | 2.08 |
| 2026-08-24 | 2.06 |
| 2026-08-21 | 2.14 |
| 2026-08-20 | 2.15 |
| 2026-08-19 | 2.22 |
| 2026-08-18 | 2.16 |
| 2026-08-17 | 2.23 |
| 2026-08-14 | 2.23 |
| 2026-08-13 | 2.15 |
| 2026-08-12 | 2.18 |
| 2026-08-11 | 2.17 |
| 2026-08-10 | 2.20 |
| 2026-08-07 | 2.20 |
| 2026-08-06 | 2.80 |
| 2026-08-05 | 2.82 |
| 2026-08-04 | 2.88 |
| 2026-08-03 | 2.86 |
| 2026-07-31 | 2.85 |
| 2026-07-30 | 2.90 |
| 2026-07-29 | 2.87 |
| 2026-07-28 | 2.93 |
| 2026-07-27 | 2.91 |
| 2026-07-24 | 2.89 |
| 2026-07-23 | 2.95 |
| 2026-07-22 | 2.92 |
| 2026-07-21 | 2.93 |
| 2026-07-20 | 2.93 |
| 2026-07-17 | 2.99 |
| 2026-07-16 | 2.95 |
| 2026-07-15 | 3.05 |
| 2026-07-14 | 2.97 |
| 2026-07-13 | 2.95 |
| 2026-07-10 | 3.04 |
| 2026-07-09 | 3.09 |
| 2026-07-08 | 3.12 |
| 2026-07-07 | 3.09 |
| 2026-07-06 | 3.07 |
| 2026-07-02 | 3.03 |
| 2026-07-01 | 2.97 |
| 2026-06-30 | 2.93 |
| 2026-06-29 | 3.01 |
| 2026-06-26 | 3.19 |
| 2026-06-25 | 3.48 |
| 2026-06-24 | 3.56 |
| 2026-06-23 | 3.55 |
| 2026-06-22 | 3.66 |
| 2026-06-18 | 3.48 |
| 2026-06-17 | 3.36 |
| 2026-06-16 | 3.26 |
| 2026-06-15 | 3.27 |
| 2026-06-12 | 3.27 |
| 2026-06-11 | 3.33 |
| 2026-06-10 | 3.22 |
| 2026-06-09 | 3.22 |
| 2026-06-08 | 3.18 |
| 2026-06-05 | 3.20 |
| 2026-06-04 | 3.10 |
| 2026-06-03 | 3.12 |
| 2026-06-02 | 3.17 |
| 2026-06-01 | 3.29 |
| 2026-05-29 | 3.47 |
| 2026-05-28 | 3.59 |
| 2026-05-27 | 3.55 |
| 2026-05-26 | 3.59 |
| 2026-05-22 | 3.51 |
| 2026-05-21 | 3.65 |
| 2026-05-20 | 3.60 |
| 2026-05-19 | 3.50 |
| 2026-05-18 | 3.51 |
| 2026-05-15 | 3.58 |
| 2026-05-14 | 3.71 |
| 2026-05-13 | 3.67 |
| 2026-05-12 | 3.80 |
| 2026-05-11 | 3.80 |
| 2026-05-08 | 3.90 |
| 2026-05-07 | 4.01 |
| 2026-05-06 | 4.08 |
| 2026-05-05 | 4.10 |
| 2026-05-04 | 4.20 |
| 2026-05-01 | 3.96 |
| 2026-04-30 | 3.79 |
| 2026-04-29 | 3.59 |
| 2026-04-28 | 3.57 |
| 2026-04-27 | 3.58 |
| 2026-04-24 | 3.56 |
| 2026-04-23 | 3.56 |
| 2026-04-22 | 3.60 |
| 2026-04-21 | 3.56 |
| 2026-04-20 | 3.77 |
| 2026-04-17 | 3.86 |
| 2026-04-16 | 3.76 |
| 2026-04-15 | 3.77 |
| 2026-04-14 | 3.79 |
| 2026-04-13 | 3.79 |
| 2026-04-10 | 3.70 |
| 2026-04-09 | 3.67 |
| 2026-04-08 | 3.65 |
| 2026-04-07 | 3.56 |
| 2026-04-06 | 3.57 |
| 2026-04-02 | 3.55 |
| 2026-04-01 | 3.65 |
| 2026-03-31 | 3.58 |
| 2026-03-30 | 3.32 |
| 2026-03-27 | 3.28 |
| 2026-03-26 | 3.40 |
| 2026-03-25 | 3.37 |
| 2026-03-24 | 3.20 |
| 2026-03-23 | 3.18 |
| 2026-03-20 | 3.18 |
| 2026-03-19 | 3.29 |
| 2026-03-18 | 3.32 |
| 2026-03-17 | 3.49 |
| 2026-03-16 | 3.49 |
| 2026-03-13 | 3.46 |
| 2026-03-12 | 3.39 |
| 2026-03-11 | 3.58 |
| 2026-03-10 | 3.66 |
| 2026-03-09 | 3.69 |
| 2026-03-06 | 3.70 |
| 2026-03-05 | 3.75 |
| 2026-03-04 | 3.98 |
| 2026-03-03 | 3.72 |
| 2026-03-02 | 3.87 |
| 2026-02-27 | 3.92 |
| 2026-02-26 | 3.97 |
| 2026-02-25 | 3.92 |
| 2026-02-24 | 3.92 |
| 2026-02-23 | 3.44 |
| 2026-02-20 | 3.43 |
| 2026-02-19 | 4.09 |
| 2026-02-18 | 4.08 |
| 2026-02-17 | 4.11 |
| 2026-02-13 | 4.17 |
| 2026-02-12 | 4.26 |
| 2026-02-11 | 4.41 |
| 2026-02-10 | 4.43 |
| 2026-02-09 | 4.45 |
| 2026-02-06 | 4.45 |
| 2026-02-05 | 4.25 |
| 2026-02-04 | 4.48 |
| 2026-02-03 | 4.70 |
| 2026-02-02 | 4.73 |
| 2026-01-30 | 4.67 |
| 2026-01-29 | 4.77 |
| 2026-01-28 | 4.77 |
| 2026-01-27 | 4.79 |
| 2026-01-26 | 4.74 |
| 2026-01-23 | 4.72 |
| 2026-01-22 | 4.82 |
| 2026-01-21 | 4.85 |
| 2026-01-20 | 4.71 |
| 2026-01-16 | 4.10 |
| 2026-01-15 | 4.28 |
| 2026-01-14 | 4.19 |
| 2026-01-13 | 4.28 |
| 2026-01-12 | 4.47 |
| 2026-01-09 | 4.70 |
| 2026-01-08 | 4.25 |
| 2026-01-07 | 3.54 |
| 2026-01-06 | 3.38 |
| 2026-01-05 | 3.70 |
| 2026-01-02 | 3.74 |
| 2025-12-31 | 3.54 |
| 2025-12-30 | 3.52 |
| 2025-12-29 | 3.51 |
| 2025-12-26 | 3.49 |
| 2025-12-24 | 3.64 |
| 2025-12-23 | 3.52 |
| 2025-12-22 | 3.55 |
| 2025-12-19 | 3.45 |
| 2025-12-18 | 3.45 |
| 2025-12-17 | 3.52 |
| 2025-12-16 | 3.64 |
| 2025-12-15 | 3.77 |
| 2025-12-12 | 3.77 |
| 2025-12-11 | 3.58 |
| 2025-12-10 | 3.60 |
| 2025-12-09 | 3.52 |
| 2025-12-08 | 3.57 |
| 2025-12-05 | 3.63 |
| 2025-12-04 | 3.60 |
| 2025-12-03 | 3.51 |
| 2025-12-02 | 3.37 |
| 2025-12-01 | 3.40 |
| 2025-11-28 | 3.52 |
| 2025-11-26 | 3.60 |
| 2025-11-25 | 3.47 |
| 2025-11-24 | 3.34 |
| 2025-11-21 | 3.29 |
| 2025-11-20 | 3.37 |
| 2025-11-19 | 3.38 |
| 2025-11-18 | 3.53 |
| 2025-11-17 | 3.59 |
| 2025-11-14 | 3.56 |
| 2025-11-13 | 3.54 |
| 2025-11-12 | 3.67 |
| 2025-11-11 | 3.72 |
| 2025-11-10 | 3.43 |
| 2025-11-07 | 3.40 |
| 2025-11-06 | 3.43 |
| 2025-11-05 | 3.61 |
| 2025-11-04 | 3.40 |
| 2025-11-03 | 3.60 |
| 2025-10-31 | 3.68 |
| 2025-10-30 | 3.11 |
| 2025-10-29 | 3.08 |
| 2025-10-28 | 3.18 |
| 2025-10-27 | 3.17 |
| 2025-10-24 | 3.13 |
| 2025-10-23 | 3.14 |
| 2025-10-22 | 3.20 |
| 2025-10-21 | 3.29 |
| 2025-10-20 | 3.17 |
| 2025-10-17 | 3.13 |
| 2025-10-16 | 3.14 |
| 2025-10-15 | 3.19 |
| 2025-10-14 | 3.11 |
| 2025-10-13 | 3.11 |
| 2025-10-10 | 3.07 |
| 2025-10-09 | 3.14 |
| 2025-10-08 | 3.14 |
| 2025-10-07 | 3.21 |
| 2025-10-06 | 3.23 |
| 2025-10-03 | 3.27 |
| 2025-10-02 | 3.26 |
| 2025-10-01 | 3.33 |
| 2025-09-30 | 3.42 |
| 2025-09-29 | 3.50 |
| 2025-09-26 | 3.44 |
| 2025-09-25 | 3.70 |
| 2025-09-24 | 3.82 |
| 2025-09-23 | 3.82 |
Showing the most recent 260 of 2,690 data points. The chart above shows the full history.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
